Welcome to our dedicated page for Embecta news (Ticker: EMBC), a resource for investors and traders seeking the latest updates and insights on Embecta stock.
Embecta Corp. reports news on its medical supplies business, centered on insulin delivery products and diabetes-care devices. The company sells pen needles, syringes and safety devices through wholesalers, distributors and institutional channels, and it has described a transition from insulin delivery toward a broader medical supplies platform.
Recurring updates include quarterly operating and financial results, cash dividend declarations, conference participation, board leadership changes, operational updates, capital-structure matters, material agreements, and regulatory or clinical disclosures tied to its device portfolio and manufacturing activities.
Embecta Corp. (NASDAQ: EMBC) announced it will report its third-quarter financial results for fiscal year 2022 on August 15, 2022. The company’s management will hold a conference call at 8:00 a.m. ET to discuss results and provide an operational update. Embecta is positioned as a significant player in diabetes care following its spin-off from Becton, Dickinson and Company on April 1, 2022. The live webcast of the call will be accessible through the company’s investor relations website.
Embecta Corp. (Nasdaq: EMBC) reported Q2 2022 revenues of $274.5 million, a decline of 3.4% year-over-year. U.S. revenues dropped 5.8%, while international revenues saw a slight decrease of 0.8%. Net income was $79.6 million, down from $107.9 million in Q2 2021. Gross profit margin rose to 69.7%. For the first half of 2022, total revenue was $563.8 million, down 1.0%, with a net income of $178.4 million. The company anticipates a significant revenue decrease of about 7% for the second half of FY 2022, projecting revenues around $555 million due to continuing supply chain challenges.
Embecta Corp. (Nasdaq: EMBC) has announced its participation in two significant investor conferences. The 2022 RBC Capital Markets Global Healthcare Conference will feature a fireside chat on May 18 at 9:30 a.m. ET at the Intercontinental NY Barclay Hotel. Furthermore, the Piper Sandler Ophthalmology and Diabetes Symposium will include a virtual fireside chat on May 25 at 12:00 p.m. ET. Both presentations will be available for replay on the company’s investor relations website.
With nearly 100 years of experience in diabetes care, Embecta aims to empower diabetes patients worldwide.
Embecta Corp. (NASDAQ: EMBC) announced it will release its financial results for Q2 of fiscal 2022 on May 13, 2022, before market opening. A conference call is set for 8:00 AM ET to discuss the results, provide business updates, and share financial guidance for 2022. Participants can join via phone or a live webcast on the company's investor website. An audio replay will be available post-call. Embecta, focused on diabetes care, leverages a century of insulin delivery experience to support individuals with diabetes.
Embecta Corp. has launched as a leading global diabetes care company, with a history stretching back to 1924. As the largest producer of diabetes injection devices, Embecta manufactures around 8 billion devices annually, serving approximately 30 million patients worldwide. The company estimates the insulin delivery market to be valued at $6 billion to $8 billion per year. With operations spanning over 100 countries and a dedicated workforce of 2,000, Embecta aims to enhance shareholder value through strategic independence and innovation in diabetes care.